Significant Growth in Operating Profit
Operating profit increased by 598% year-on-year, attributed to the growth of LENVIMA and Dayvigo, effective cost control, and a reduction in tax charges.
Leqembi Approval and Expansion
Leqembi received full approval in the United States and Japan, with ongoing reviews in the EU and China. The company aims to launch in Japan by the end of 2023.
Revenue Growth Despite Challenges
Revenue grew by 4% year-on-year, overcoming negative factors such as the expiration of the HUMIRA co-promotion agreement in Japan.
Upward Revision of Full Year Profit Forecast
The company announced an upward revision of its profit forecast for the year by JPY 4 billion.